

Patient Name	: Mr MR.DUMMY	Sample Collected	: Apr 26, 2024, 01:00 PM.
DOB/Age/Gender	: 23 Y/Male	Report Date	: May 07, 2024,03:34 PM.
Patient ID / UHID	: 8053078/RCL7249629	Barcode No	: MD072021
Referred By	: Dr. X	Report Status	: Final Report
Sample Type	: EDTA Plasma\$1		

Hepatitis B (HBV) DNA Detector, Qualitative

Test Principle	Real Time Polymerase Chain Reaction
Target	S-gene
Equipment	Rotor-Gene Q / Bio-Rad CFX-96
Result	Not Detected

RESULT INTERPRETATION:

Observations	Result	Comments
Amplification in both Internal Control(IC) and S Gene	Target Detected	HBV DNA Detected
Amplification in Internal Control (IC) only	Target Not Detected	HBV DNA Not Detected
No amplification in Internal Control (IC)	Inconclusive	Testing of a new specimen is recommended.

LIMITATION OF ASSAY :

1. PCR is a highly sensitive technique; common reasons for paradoxical results are contamination during specimen collection, selection of inappropriate specimen and inherent PCR inhibitors in the sample.
2. Laboratory tests are merely a tool to assist in the diagnosing process and should be clinically correlated by the Referring Physician.

CLINICAL UTILITY :

1. Estimate of level of HBV replication at baseline and during treatment
2. Document rapid (RVR) and early (EVR) virologic response
3. Guide duration of antiviral therapy
4. Confirm resolution of infection and sustained virologic response (SVR)

CLINICAL BACKGROUND :

1. Chronic hepatitis B virus (HBV) infection affects over 350 million people worldwide and over 1 million die annually of HBV-related chronic liver disease.
2. Although many individuals eventually achieve a state of non-replicative infection, the prolonged immunologic response to infection may lead to the development of cirrhosis, liver failure, or hepatocellular carcinoma (HCC) in up to 40% of patients.
3. HBV which predominantly transmit through the parenteral route, pose a serious "silent epidemic" challenge to India. The average estimated carrier rate of hepatitis B virus (HBV) in India is 3.7 %, with a total pool of over 40 million carriers
4. Quantitation of HBV DNA is useful in the evaluation and management of the patients with chronic HBV infection. Current WHO guidelines also recommend HBV DNA viral load testing in disease response and/or treatment response

COMMENTS :


1. Laboratory evaluation of HBV infection status should begin with HBV serologic testing, including testing for the presence of hepatitis B surface antigen.
2. A diagnosis of chronic HBV infection should not be based solely on the presence of detectable or quantifiable HBV DNA in a single serum specimen.
3. An "Undetected" HBV DNA test result in conjunction with a positive anti-HBV status does not exclude the possibility of a resolved HBV infection. When clinically indicated, patients should be retested for HBV DNA in 1 to 2 months, to distinguish between past/resolved HBV infection and chronic HBV infection with episodic viral replication.

NOTE :

1. All test outcomes are subject to the nature of the sample received by the Laboratory.



Dr. Amit Singh
MD Microbiology
Consultant Microbiologist



Hemraj Singh
M.Sc. (Biotechnology)
Section Head, Mol. & Infectious



Prof. Ashok Rattan
MD (Microbiology), MAMS.



Booking Centre :- DEMO PARTNER CHENNAI, DEMO PARTNER CHENNAI
Processing Lab :-

928-909-0609

ccsupport@redcliffelabs.com

www.redcliffelabs.com

All Lab results are subject to clinical interpretation by qualified medical professional and this report is not subject to use for any medico-legal purpose.

Patient Name	: Mr MR.DUMMY	Sample Collected	: Apr 26, 2024, 01:00 PM.
DOB/Age/Gender	: 23 Y/Male	Report Date	: May 07, 2024,03:34 PM.
Patient ID / UHID	: 8053078/RCL7249629	Barcode No	: MD072021
Referred By	: Dr. X	Report Status	: Final Report
Sample Type	: EDTA Plasma\$1		

2. Within 7 days after reporting, sample repetitions are acceptable at the request of the Referring Physician.
3. Test results are not valid for medico legal purposes.


*** End Of Report ***

Disclaimer: Method given in report are only indicative and can be changed depending upon type of machine and kit available at time of testing.

Not all tests at all locations are under NABL scope. Availability of tests under NABL scope varies from lab to lab.



Dr. Amit Singh
MD Microbiology
Consultant Microbiologist



Hemraj Singh
M.SC. (Biotechnology)
Section Head, Mol. & Infectious



Prof. Ashok Rattan
MD (Microbiology), MAMS.



Booking Centre :- DEMO PARTNER CHENNAI, DEMO PARTNER CHENNAI
Processing Lab :-

📞 928-909-0609

✉️ ccsupport@redcliffelabs.com

🌐 www.redcliffelabs.com

All Lab results are subject to clinical interpretation by qualified medical professional and this report is not subject to use for any medico-legal purpose.

Terms and Conditions of Reporting

1. The presented findings in the Reports are intended solely for informational and interpretational purposes by the referring physician or other qualified medical professionals possessing a comprehensive understanding of reporting units, reference ranges, and technological limitations. The laboratory shall not be held liable for any interpretation or misinterpretation of the results, nor for any consequential or incidental damages arising from such interpretation.
2. It is to be presumed that the tests performed pertain to the specimen/sample attributed to the Customer's name or identification. It is presumed that the verification particulars have been cleared out by the customer or his/her representation at the point of generation of said specimen / sample. It is hereby clarified that the reports furnished are restricted solely to the given specimen only.
3. It is to be noted that variations in results may occur between different laboratories and over time, even for the same parameter for the same Customer. The assays are performed and conducted in accordance with standard procedures, and the reported outcomes are contingent on the specific individual assay methods and equipment(s) used, as well as the quality of the received specimen.
4. This report shall not be deemed valid or admissible for any medico-legal purposes.
5. The Customers assume full responsibility for apprising the Company of any factors that may impact the test finding. These factors, among others, includes dietary intake, alcohol, or medication / drug(s) consumption, or fasting. This list of factors is only representative and not exhaustive.

DISCLAIMER

This is a sample report provided for demonstration purposes only and does not represent an actual patient report. Test results, reference ranges, methodologies, instrumentation, and report formats may vary depending on the laboratory performing the test. The format and representation shown are indicative of reports generated by the National Reference Laboratory of Redcliffe Labs, Noida. This sample report should not be used for medical interpretation, diagnosis, or treatment decisions.